❌

Normal view

  • ✇TechCrunch
  • ChatGPT is testing a mysterious new feature called ‘study together’ Julie Bort
    Some ChatGPT subscribers are reporting a new feature appearing in their drop-down list of available tools called “Study Together.” The mode is apparently the chatbot’s way of becoming a better educational tool. Rather than providing answers to prompts, some say it asks more questions and requires the human to answer, like OpenAI’s answer to Google’s […]
     

ChatGPT is testing a mysterious new feature called ‘study together’

8 July 2025 at 03:53
Some ChatGPT subscribers are reporting a new feature appearing in their drop-down list of available tools called “Study Together.” The mode is apparently the chatbot’s way of becoming a better educational tool. Rather than providing answers to prompts, some say it asks more questions and requires the human to answer, like OpenAI’s answer to Google’s […]

Human embryo research: how to move towards a 28-day limit

Nature, Published online: 01 July 2025; doi:10.1038/d41586-025-02016-9

The decades-old limit on how long human embryos can be grown in culture is under debate. A new road map outlines how to extend the length of culture responsibly.
  • ✇MRD
  • Biomarkers in adjuvant and neoadjuvant treatment of melanoma Julian Kött · Christoffer Gebhardt
    Dermatologie (Heidelb). 2025 Jun;76(6):361-364. doi: 10.1007/s00105-025-05506-z. Epub 2025 May 7.ABSTRACTBACKGROUND: Personalized treatment of melanoma is becoming increasingly more important. Biomarkers offer the possibility of controlling treatment more precisely and reducing side effects.OBJECTIVE: The aim of this text is to provide an overview of current tissue-based, blood-based and radiological biomarkers and their clinical application in melanomas.MATERIAL AND METHODS: A literature resear
     

Biomarkers in adjuvant and neoadjuvant treatment of melanoma

7 May 2025 at 18:00

Dermatologie (Heidelb). 2025 Jun;76(6):361-364. doi: 10.1007/s00105-025-05506-z. Epub 2025 May 7.

ABSTRACT

BACKGROUND: Personalized treatment of melanoma is becoming increasingly more important. Biomarkers offer the possibility of controlling treatment more precisely and reducing side effects.

OBJECTIVE: The aim of this text is to provide an overview of current tissue-based, blood-based and radiological biomarkers and their clinical application in melanomas.

MATERIAL AND METHODS: A literature research and analysis of current studies on biomarkers in adjuvant and neoadjuvant treatment of melanomas were carried out and relevant congress contributions were additionally included.

RESULTS: Tissue-based programmed cell death 1 ligand 1 (PD-L1) expression, interferon gamma (IFNγ) signature, gene expression profiles (GEP) and tumor mutational burden (TMB) are of prognostic and predictive relevance. Blood-based circulating tumor DNA (ctDNA) in the sense of a liquid biopsy should be emphasized as a personalized biomarker for longitudinal tracking during treatment or aftercare. Positron emission tomography computed tomography (PET-CT) and body composition enable an improved assessment of treatment efficiency. There are currently no data from prospective validation studies on these biomarkers; initial data from the NivoMela study are awaited.

CONCLUSION: The combination of tissue-based, blood-based and radiological biomarkers in terms of multiparametric approaches is promising but further prospective validation is needed for broad clinical use. These are currently not comprehensively implemented in the clinical routine in centers or in remuneration procedures.

PMID:40335648 | DOI:10.1007/s00105-025-05506-z

Cross-sectional and longitudinal association of seven DNAm-based predictors with metabolic syndrome and type 2 diabetes

To date, various epigenetic clocks have been constructed to estimate biological age, most commonly using DNA methylation (DNAm). These include “first-generation” clocks such as DNAmAgeHorvath and “second-gener...

Rare disease gene association discovery in the 100,000 Genomes Project

Nature, Published online: 26 February 2025; doi:10.1038/s41586-025-08623-w

A rare variant burden analytical framework for Mendelian diseases was developed and applied to data from the 100,000 Genomes Project, identifying 69 probable new disease–gene associations.

Heritable polygenic editing: the next frontier in genomic medicine?

Nature, Published online: 08 January 2025; doi:10.1038/s41586-024-08300-4

We discuss the potential consequences and ethical concerns of polygenic genome editing of human embryos to alter specific variants associated with polygenic diseases, highlighting the possibility of reducing disease susceptibility while exacerbating health inequalities.

Label-free detection and profiling of individual solution-phase molecules

Nature, Published online: 08 May 2024; doi:10.1038/s41586-024-07370-8

Enhanced light–molecule interactions in high-finesse fibre-based Fabry–Pérot microcavities are used to detect and profile individual unlabelled solution-phase biomolecules, leading to potential applications in the life and chemical sciences.

Proteome-scale discovery of protein degradation and stabilization effectors

Nature, Published online: 20 March 2024; doi:10.1038/s41586-024-07224-3

A synthetic proteome-scale strategy enables the identification of a diverse range of human proteins that can induce the degradation or stabilization of a target protein in a proximity-dependent way.

Evolutionary trajectories of small cell lung cancer under therapy

Nature, Published online: 13 March 2024; doi:10.1038/s41586-024-07177-7

We uncover key processes of the genomic evolution of small cell lung cancer under therapy, identify the common ancestor as the source of clonal diversity at relapse and show central genomic patterns associated with drug response.

SPLASH: A statistical, reference-free genomic algorithm unifies biological discovery

Genomics workflows typically map reads onto a reference genome as the foundation for downstream analyses. However, this poses severe limitations for biological discovery when references are incomplete or nonexistent, and even for intensely studied genomes with rich population-level diversity. SPLASH is a highly efficient framework for statistics-driven analysis of sequence variation directly from raw sequencing data, overcoming previous limitations.
❌